| ชื่อเรื่อง | : | Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine |
| นักวิจัย | : | Tang M.W. , Rhee S.-Y. , Bertagnolio S. , Ford N. , Holmes S. , Sigaloff K.C. , Hamers R.L. , De Wit T.F.R. , Fleury H.J. , Kanki P.J. , Ruxrungtham K. , Hawkins C.A. , Wallis C.L. , Stevens W. , Van Zyl G.U. , Manosuthi W. , Hosseinipour M.C. , Ngo-Giang-Huong N. , Belec L. , Peeters M. , Aghokeng A. , Bunupuradah T. , Burda S. , Cane P. , Cappelli G. , Charpentier C. , Dagnra A.Y. , Deshpande A.K. , El-Katib Z. , Eshleman S.H. , Fokam J. , Gody J.-C. , Katzenstein D. , Koyalta D.D. , Kumwenda J.J. , Lallemant M. , Lynen L. , Marconi V.C. , Margot N.A. , Moussa S. , Ndung'U T. , Nyambi P.N. , Orrell C. , Schapiro J.M. , Schuurman R. , Sirivichayakul S. , Smith D. , Zolfo M. , Jordan M.R. , Shafer R.W. |
| คำค้น | : | - |
| หน่วยงาน | : | มหาวิทยาลัยเชียงใหม่ |
| ผู้ร่วมงาน | : | - |
| ปีพิมพ์ | : | 2556 |
| อ้างอิง | : | 00221899 , 10.1093/infdis/jit114 , 23687292 , JIDIA , http://www.scopus.com/inward/record.url?eid=2-s2.0-84878329003&partnerID=40&md5=7faa842164431e19965a00c998235619 , http://cmuir.cmu.ac.th/handle/6653943832/919 |
| ที่มา | : | - |
| ความเชี่ยวชาญ | : | - |
| ความสัมพันธ์ | : | - |
| ขอบเขตของเนื้อหา | : | - |
| บทคัดย่อ/คำอธิบาย | : | Background The World Health Organization Antiretroviral Treatment Guidelines recommend phasing-out stavudine because of its risk of long-term toxicity. There are two mutational pathways of stavudine resistance with different implications for zidovudine and tenofovir cross-resistance, the primary candidates for replacing stavudine. However, because resistance testing is rarely available in resource-limited settings, it is critical to identify the cross-resistance patterns associated with first-line stavudine failure.MethodsWe analyzed HIV-1 resistance mutations following first-line stavudine failure from 35 publications comprising 1,825 individuals. We also assessed the influence of concomitant nevirapine vs. efavirenz, therapy duration, and HIV-1 subtype on the proportions of mutations associated with zidovudine vs. tenofovir cross-resistance.ResultsMutations with preferential zidovudine activity, K65R or K70E, occurred in 5.3% of individuals. Mutations with preferential tenofovir activity, ≥two thymidine analog mutations (TAMs) or Q151M, occurred in 22% of individuals. Nevirapine increased the risk of TAMs, K65R, and Q151M. Longer therapy increased the risk of TAMs and Q151M but not K65R. Subtype C and CRF01-AE increased the risk of K65R, but only CRF01-AE increased the risk of K65R without Q151M.ConclusionsRegardless of concomitant nevirapine vs. efavirenz, therapy duration, or subtype, tenofovir was more likely than zidovudine to retain antiviral activity following first-line d4T therapy. © The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. |
| บรรณานุกรม | : |
Tang M.W. , Rhee S.-Y. , Bertagnolio S. , Ford N. , Holmes S. , Sigaloff K.C. , Hamers R.L. , De Wit T.F.R. , Fleury H.J. , Kanki P.J. , Ruxrungtham K. , Hawkins C.A. , Wallis C.L. , Stevens W. , Van Zyl G.U. , Manosuthi W. , Hosseinipour M.C. , Ngo-Giang-Huong N. , Belec L. , Peeters M. , Aghokeng A. , Bunupuradah T. , Burda S. , Cane P. , Cappelli G. , Charpentier C. , Dagnra A.Y. , Deshpande A.K. , El-Katib Z. , Eshleman S.H. , Fokam J. , Gody J.-C. , Katzenstein D. , Koyalta D.D. , Kumwenda J.J. , Lallemant M. , Lynen L. , Marconi V.C. , Margot N.A. , Moussa S. , Ndung'U T. , Nyambi P.N. , Orrell C. , Schapiro J.M. , Schuurman R. , Sirivichayakul S. , Smith D. , Zolfo M. , Jordan M.R. , Shafer R.W. . (2556). Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine.
เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ . Tang M.W. , Rhee S.-Y. , Bertagnolio S. , Ford N. , Holmes S. , Sigaloff K.C. , Hamers R.L. , De Wit T.F.R. , Fleury H.J. , Kanki P.J. , Ruxrungtham K. , Hawkins C.A. , Wallis C.L. , Stevens W. , Van Zyl G.U. , Manosuthi W. , Hosseinipour M.C. , Ngo-Giang-Huong N. , Belec L. , Peeters M. , Aghokeng A. , Bunupuradah T. , Burda S. , Cane P. , Cappelli G. , Charpentier C. , Dagnra A.Y. , Deshpande A.K. , El-Katib Z. , Eshleman S.H. , Fokam J. , Gody J.-C. , Katzenstein D. , Koyalta D.D. , Kumwenda J.J. , Lallemant M. , Lynen L. , Marconi V.C. , Margot N.A. , Moussa S. , Ndung'U T. , Nyambi P.N. , Orrell C. , Schapiro J.M. , Schuurman R. , Sirivichayakul S. , Smith D. , Zolfo M. , Jordan M.R. , Shafer R.W. . 2556. "Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine".
เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ . Tang M.W. , Rhee S.-Y. , Bertagnolio S. , Ford N. , Holmes S. , Sigaloff K.C. , Hamers R.L. , De Wit T.F.R. , Fleury H.J. , Kanki P.J. , Ruxrungtham K. , Hawkins C.A. , Wallis C.L. , Stevens W. , Van Zyl G.U. , Manosuthi W. , Hosseinipour M.C. , Ngo-Giang-Huong N. , Belec L. , Peeters M. , Aghokeng A. , Bunupuradah T. , Burda S. , Cane P. , Cappelli G. , Charpentier C. , Dagnra A.Y. , Deshpande A.K. , El-Katib Z. , Eshleman S.H. , Fokam J. , Gody J.-C. , Katzenstein D. , Koyalta D.D. , Kumwenda J.J. , Lallemant M. , Lynen L. , Marconi V.C. , Margot N.A. , Moussa S. , Ndung'U T. , Nyambi P.N. , Orrell C. , Schapiro J.M. , Schuurman R. , Sirivichayakul S. , Smith D. , Zolfo M. , Jordan M.R. , Shafer R.W. . "Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine."
เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ , 2556. Print. Tang M.W. , Rhee S.-Y. , Bertagnolio S. , Ford N. , Holmes S. , Sigaloff K.C. , Hamers R.L. , De Wit T.F.R. , Fleury H.J. , Kanki P.J. , Ruxrungtham K. , Hawkins C.A. , Wallis C.L. , Stevens W. , Van Zyl G.U. , Manosuthi W. , Hosseinipour M.C. , Ngo-Giang-Huong N. , Belec L. , Peeters M. , Aghokeng A. , Bunupuradah T. , Burda S. , Cane P. , Cappelli G. , Charpentier C. , Dagnra A.Y. , Deshpande A.K. , El-Katib Z. , Eshleman S.H. , Fokam J. , Gody J.-C. , Katzenstein D. , Koyalta D.D. , Kumwenda J.J. , Lallemant M. , Lynen L. , Marconi V.C. , Margot N.A. , Moussa S. , Ndung'U T. , Nyambi P.N. , Orrell C. , Schapiro J.M. , Schuurman R. , Sirivichayakul S. , Smith D. , Zolfo M. , Jordan M.R. , Shafer R.W. . Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine. เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ ; 2556.
|
ridm@nrct.go.th ระบบคลังข้อมูลงานวิจัยไทย รายการโปรดที่คุณเลือกไว้
